Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $142.7 million.

  • Crinetics Pharmaceuticals' Operating Expenses rose 6256.71% to $142.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.4 million, marking a year-over-year increase of 5574.19%. This contributed to the annual value of $339.9 million for FY2024, which is 4998.3% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Operating Expenses stood at $142.7 million for Q3 2025, which was up 6256.71% from $130.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Operating Expenses registered a high of $142.7 million during Q3 2025, and its lowest value of $22.9 million during Q1 2021.
  • In the last 5 years, Crinetics Pharmaceuticals' Operating Expenses had a median value of $56.7 million in 2023 and averaged $67.0 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Operating Expenses soared by 2414.45% in 2023 and then skyrocketed by 6256.71% in 2025.
  • Crinetics Pharmaceuticals' Operating Expenses (Quarter) stood at $32.0 million in 2021, then surged by 50.99% to $48.3 million in 2022, then grew by 29.82% to $62.7 million in 2023, then soared by 51.21% to $94.7 million in 2024, then skyrocketed by 50.65% to $142.7 million in 2025.
  • Its last three reported values are $142.7 million in Q3 2025, $130.1 million for Q2 2025, and $111.8 million during Q1 2025.